Corporate Information | |
Chairman’s Statement | 4 |
2021 Interim Results & Business Updates | 5 |
Interim 2022 Financial Results | 11 |
Financial Summary | 13 |
Operations Review | |
Oncology/Immunology |
16 28 |
Use of Non-GAAP Financial Measures and Reconciliation | 29 |
Group Capital Resources | 31 |
Other Information | 36 |
Disclosure of Interests | 40 |
Long Term Incentive Plan | 47 |
Corporate Governance | 50 |
Changes in Information of Directors | 51 |
Interim Unaudited Condensed Consolidated Financial Statements | 52 |
References and Abbreviations | 78 |
Information for Shareholders | |